Clinical Evidence

Thank you for submitting our form.

You now have open access to read and download our Clinical Evidence pieces for Chronic, Acute, and In-Center facilities. We hope these pieces may help you learn more about the details, and possible benefits, of our products and services.

  • NxStage System One FIRST and ONLY clearance for Home Nocturnal Hemodialysis
  • Home Hemodialysis Clinical Evidence: Part 1 - Cardiac injury and dialysis
  • Home Hemodialysis Clinical Evidence: Part 2 - Breaking Down the Prescription Barriers to Home Hemodialysis
  • Home Hemodialysis Clinical Evidence: Part 3 - Home Dialysis Comparitive Outcomes and Patient Selection
  • SHIFT therapy with the NxStage System One provides adequate volume and solute control, while allowing for flexibility for staffing.
  • When compared to conventional blood tubing, Streamline® reduced dialysate flow and conserved fresh water while improving average Kt/V.
  • Streamline® improved adequacy, reduced heparin utilization and made more efficient use of dialyzers when compared to conventional bloodlines.
  • Compared to conventional bloodlines, Streamline® provided significantly lower costs per treatment and reductions in heparin usage and medical waste.
  • A Prospective Study of Routine Heparin Free Hemodialysis (HFD) with Streamline® Bloodlines (SL) in a Large Tertiary Acute Care Inpatient Practice
  • When compared to conventional bloodlines, Streamline® enabled higher blood flow rates, which improved average Kt/V.
  • Ciprofloxacin Dosing in Critically Ill Patients Receiving SHIFT Hemofiltration or Hemodialysis Renal Replacement Therapies
  • Probability of Target Attainment for Gentamicin Dosing in Modeled Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapies
  • Monte Carlo Simulations to Determine Optimal Levofloxacin Dosing for Gram Negative Infections in Patients Receiving SHIFT Renal Replacement Therapy
  • Monte Carlo Simulations to Determine Optimal Levofloxacin Regimens for Streptococcus pneumoniae Infections in Patients Receiving SHIFT Renal Replacement Therapy
  • Cefepime Dosing in Modeled Critically Ill Patients Receiving SHIFT Hemofiltration or Hemodialysis Renal Replacement Therapies
  • Identification of Optimal Ceftazidime Dosing Regimens in Modeled Critically Ill Patients Receiving SHIFT Renal Replacement Therapy
  • Use of Monte Carlo Simulation to Determine Optimal Meropenem Regimens in Patients Receiving SHIFT Renal Replacement Therapy
  • Evaluation of Piperacillin/Tazobactam Regimens in Patients with SHIFT Renal Replacement Therapy